Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Nomenclature01:17

Drug Nomenclature

1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Drug Regulation01:25

Drug Regulation

1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Standards of Care I01:22

Standards of Care I

689
Federal statutes profoundly impact nursing practice, providing critical guidelines to ensure patient care is equitable, accessible, and of the highest quality. The following laws address distinct aspects of healthcare provision and patient rights:
689
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

158
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
158

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to 'Methodological concerns and a lack of evidence for reforming regulatory exclusivities for pharmaceuticals'.

Nature biotechnology·2026
Same author

Modification patents across multiple NDAs in pharmaceutical protections.

Health affairs scholar·2026
Same author

Tear down the wall: why requiring the FDA and the PTO to share information will improve the decision-making of both agencies.

Journal of law and the biosciences·2026
Same author

The New Clinical Investigation exclusivity: a substantial source of monopoly time for brand drugs.

Nature biotechnology·2025
Same author

Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act.

PLoS medicine·2024
Same author

Leading with the trailing edge: facilitating patient choice for insulin products.

Journal of law and the biosciences·2023

Related Experiment Video

Updated: Jul 1, 2025

Applications for Open Source Microplate-Compatible Illumination Panels
08:48

Applications for Open Source Microplate-Compatible Illumination Panels

Published on: October 3, 2019

7.5K

NIH Licensing Would Benefit from Free-Market Provisions.

Robin Feldman, Zachary Rosen

    The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
    |March 4, 2024
    PubMed
    Summary

    Government support for free markets effectively drives pharmaceutical innovation. The National Institutes of Health (NIH) can foster this by incorporating anti-competitive clauses into licensing agreements, promoting research without new legislation.

    Keywords:
    Free MarketGovernment LicensingNIHPatentTrade Secret

    Related Experiment Videos

    Last Updated: Jul 1, 2025

    Applications for Open Source Microplate-Compatible Illumination Panels
    08:48

    Applications for Open Source Microplate-Compatible Illumination Panels

    Published on: October 3, 2019

    7.5K

    Area of Science:

    • Health Policy
    • Pharmaceutical Sciences
    • Economics

    Background:

    • Government policies significantly influence pharmaceutical innovation.
    • Free market principles are often cited as drivers of innovation.
    • The role of intellectual property and licensing in research is critical.

    Purpose of the Study:

    • To evaluate the effectiveness of government encouragement of free markets in fostering pharmaceutical innovation.
    • To explore how the National Institutes of Health (NIH) can utilize existing mechanisms to support innovation.
    • To identify strategies for the NIH to promote innovation through licensing agreements.

    Main Methods:

    • Analysis of existing government policies and their impact on pharmaceutical R&D.
    • Examination of licensing agreements used by the NIH.
    • Assessment of "free-market provisions" and their potential to curb anti-competitive behavior.

    Main Results:

    • Government encouragement of free markets is a potent strategy for enhancing pharmaceutical innovation.
    • The NIH can implement "free-market provisions" within its current licensing agreements.
    • These provisions can effectively discourage anti-competitive and research-impeding actions.

    Conclusions:

    • The NIH possesses the capacity to significantly bolster pharmaceutical innovation through strategic licensing.
    • Legislative changes are not necessarily required to foster a more innovative environment.
    • Implementing specific "free-market provisions" in NIH licensing agreements is a viable and effective approach.